Replimune Group (REPL) News Today $13.75 +0.73 (+5.61%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Wedbush Brokers Raise Earnings Estimates for Replimune GroupReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Research analysts at Wedbush increased their Q3 2025 earnings estimates for shares of Replimune Group in a note issued to investors on Tuesday, January 21st. Wedbush analyst R. Driscoll now expects that the company will earn ($0.63) per share foJanuary 23 at 9:00 AM | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Up 6% After Analyst UpgradeJanuary 23 at 1:13 AM | americanbankingnews.comReplimune price target raised to $21 from $17 at H.C. WainwrightJanuary 22 at 9:06 PM | markets.businessinsider.comStrong Buy Rating for Replimune Group Due to Promising RP1 + Opdivo Results and Favorable FDA ReviewJanuary 22 at 9:06 PM | markets.businessinsider.comReplimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal yearJanuary 22 at 9:06 PM | msn.comBMO Capital Markets Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) StockBMO Capital Markets upped their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday.January 22 at 12:21 PM | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 6% After Analyst UpgradeReplimune Group (NASDAQ:REPL) Trading Up 6% Following Analyst UpgradeJanuary 22 at 10:43 AM | marketbeat.comReplimune Group (NASDAQ:REPL) Given New $21.00 Price Target at HC WainwrightHC Wainwright increased their price target on Replimune Group from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Wednesday.January 22 at 8:23 AM | marketbeat.comReplimune announces BLA acceptance, priority review for RP1January 21 at 11:00 PM | markets.businessinsider.comReplimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma TherapyJanuary 21 at 5:59 PM | uk.finance.yahoo.comReplimune stock price target raised to $27 by BMO CapitalJanuary 21 at 5:59 PM | msn.comReplimune stock soars on FDA priority review for melanoma treatmentJanuary 21 at 12:59 PM | in.investing.comFDA accepts Replimune's advanced melanoma therapy BLAJanuary 21 at 12:59 PM | msn.comReplimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced MelanomaJanuary 21 at 12:59 PM | markets.businessinsider.comReplimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock SurgesJanuary 21 at 12:59 PM | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?January 21 at 12:10 PM | marketbeat.comReplimune Group (REPL) Receives a Buy from BarclaysJanuary 16, 2025 | markets.businessinsider.comReplimune Group’s Strategic Advances Highlight Promising Potential in Oncolytic Virus TherapyJanuary 14, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?Replimune Group (NASDAQ:REPL) Shares Down 6.6% - Time to Sell?January 14, 2025 | marketbeat.comBarclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL)Barclays PLC lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 165.5% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 158,491 shares of the company's stock after acquiring an additional 98,791 shares during the quarter.January 12, 2025 | marketbeat.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2025 | globenewswire.comReplimune announces RP2 development program advancesJanuary 8, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Up 9.5% - Should You Buy?Replimune Group (NASDAQ:REPL) Shares Up 9.5% - What's Next?January 2, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from BrokeragesReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) has earned an average rating of "Buy" from the eight research firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The aJanuary 1, 2025 | marketbeat.comGeode Capital Management LLC Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)Geode Capital Management LLC grew its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 17.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,428,301 shares of the compaDecember 30, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLCBarclays PLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 165.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 158,491 shares of the company's stock after purchasing an additional 98,791 shares during the perioDecember 28, 2024 | marketbeat.comReplimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | globenewswire.comState Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL)State Street Corp boosted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 102.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,340,042 shares of the company's stock after purchasing an additional 1,182,181 sDecember 23, 2024 | marketbeat.comJane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL)Jane Street Group LLC cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 51.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 262,248 shares of the company's stock after selling 274,078 shDecember 22, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 8.2% - Here's WhyReplimune Group (NASDAQ:REPL) Trading Up 8.2% - Here's What HappenedDecember 20, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel Sells 10,000 SharesDecember 19, 2024 | insidertrades.comInsider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of StockReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.December 18, 2024 | marketbeat.comWellington Management Group LLP Decreases Position in Replimune Group, Inc. (NASDAQ:REPL)Wellington Management Group LLP reduced its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 40.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,398 shares of thDecember 18, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Trading Down 4.7% - Here's WhyReplimune Group (NASDAQ:REPL) Shares Down 4.7% - Should You Sell?December 17, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in NovemberReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily trading volume, of 828,800 shares, the short-interest ratio is currently 6.7 days.December 14, 2024 | marketbeat.comFmr LLC Sells 120,776 Shares of Replimune Group, Inc. (NASDAQ:REPL)Fmr LLC trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 626,412 shares of the company's stock after selling 120,776 shares duriDecember 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL)Charles Schwab Investment Management Inc. grew its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 12.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 484,797 shares of the company's stock after acquiring an additional 52,498 shares during tDecember 13, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 44,153 Shares of Replimune Group, Inc. (NASDAQ:REPL)Jacobs Levy Equity Management Inc. cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 52.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,521 shares ofDecember 10, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsShares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been assigned an average rating of "Buy" from the eight brokerages that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to theDecember 7, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)December 5, 2024 | markets.businessinsider.comReplimune Group, Inc. (NASDAQ:REPL) is Redmile Group LLC's 8th Largest PositionRedmile Group LLC lessened its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 14.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,781,183 shares of the company's stock aDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $8.37 Million Stake in Replimune Group, Inc. (NASDAQ:REPL)Parkman Healthcare Partners LLC grew its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 45.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 763,747 shares of the company's stock after aDecember 4, 2024 | marketbeat.comBaker BROS. Advisors LP Has $121.06 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)Baker BROS. Advisors LP boosted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 10.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,045,336 shares of the company's stock after acquDecember 2, 2024 | marketbeat.comAlgert Global LLC Has $469,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)Algert Global LLC lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 49.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,763 shares of the company's stock after seDecember 1, 2024 | marketbeat.comBraidwell LP Has $33.66 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL)Braidwell LP raised its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 203.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,070,837 shares of the company's stock after acquiring an additionNovember 29, 2024 | marketbeat.comReplimune: RPL1 BLA Submission Under AA Pathway Makes It A Must WatchNovember 29, 2024 | seekingalpha.comReplimune 6.923M share Spot Secondary priced at $13.00November 26, 2024 | markets.businessinsider.comReplimune Prices Public Offering Of 6.923 Mln Common Shares At $13/ShrNovember 26, 2024 | markets.businessinsider.comReplimune Announces Pricing of Upsized Public OfferingNovember 25, 2024 | globenewswire.comOptimistic Buy Rating for Replimune Group Amid Promising Developments in Melanoma TreatmentNovember 25, 2024 | markets.businessinsider.com Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Media Mentions By Week REPL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.710.62▲Average Medical News Sentiment REPL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼193▲REPL Articles Average Week Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalyst Pharmaceuticals News Merus News Bausch Health Companies News Kymera Therapeutics News SpringWorks Therapeutics News Amneal Pharmaceuticals News Recursion Pharmaceuticals News Gemini Therapeutics News Edgewise Therapeutics News HUTCHMED News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
